Last updated: February 23, 2026
What is NDC 00069-1001?
NDC 00069-1001 corresponds to Rituximab, a monoclonal antibody used primarily to treat non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune disorders. It is marketed under the brand name Rituxan by Genentech (a Roche subsidiary).
Market Overview
Clinical Indications and Revenue Drivers
- Primary Indications: Non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis, polyangiitis.
- Market Penetration: Rituximab's patent expiry occurred in 2018 in the U.S., leading to biosimilar entry.
- Competitive Landscape: Biosimilars launched by Sandoz, Celltrion, and others since 2019. Bios antiviral biosimilars have taken a significant market share, impacting branded Rituximab prices.
Market Size and Growth
- 2022 U.S. Rituximab Market: ~$1.2 billion.
- Global Market (2022): Estimated at $3.8 billion, driven by expanding indications and developing markets.
- Compound Annual Growth Rate (CAGR): Post-patent expiry, a decline of approximately 5% annually due to biosimilar competition and price erosion.
Key Markets
| Region |
2022 Revenue (USD Million) |
Growth Rate |
Comments |
| United States |
1,200 |
-10% (due to biosimilar entry) |
Largest market, high penetration |
| Europe |
900 |
-8% |
Significant biosimilar adoption |
| Asia-Pacific |
700 |
+7% |
Growth driven by increasing cancer prevalence |
| Rest of World |
1,000 |
+3% |
Emerging markets with expanding healthcare infrastructure |
Price Trends and Projections
Current Pricing (2023)
- Branded Rituximab: Approximate list price per vial (100 mg): $2,200.
- Biosimilars: Price discounts of 20–30%, with actual transaction prices often lower due to negotiations and payor discounts.
Historical Price Trends
| Year |
Branded Price per Vial |
Biosimilar Price per Vial |
Price Change (%) |
| 2018 |
$2,200 |
N/A |
Baseline |
| 2019 |
$2,200 |
$1,800 |
0% (branded stable) |
| 2020 |
$2,200 |
$1,500 |
-16.7% |
| 2021 |
$2,200 |
$1,400 |
-6.7% |
| 2022 |
$2,200 |
$1,300 |
-7.1% |
Forward Price Projections (2024-2028)
- Branded Rituximab: Expected to stabilize around $2,000–$2,200 per vial, with minimal fluctuations.
- Biosimilars: Anticipate further price reductions due to increased competition, with prices possibly declining to $1,000–$1,200 per vial in mature markets by 2028.
- Market Dynamics: Price erosion will continue, but protoned with demand-driven price stabilization for certain indications.
Factors Influencing Future Pricing
- Patent expirations: Additional biosimilar entrants could further decrease prices.
- Manufacturing costs: Advances enable more cost-effective biosimilar production, facilitating price cuts.
- Pricing policies: New regulations and policies may influence pricing strategies, especially in Europe and the U.S.
- Market demand: Growth in autoimmune and oncology indications sustains demand, somewhat offsetting price declines.
Key Takeaways
- The U.S. market for Rituximab declined sharply post-2018 due to biosimilar competition but remains significant.
- Biosimilar prices have lowered branded drug prices by approximately 20–30%, with further drops expected.
- In emerging markets, prices remain higher relative to disposable income, maintaining revenue potential.
- Future revenue depends heavily on biosimilar market share growth and regional pricing policies.
- The total global Rituximab market is expected to contract slightly through 2028 due to pricing pressures but will remain sizable.
FAQs
1. What are the primary biosimilar competitors for NDC 00069-1001?
Sandoz, Celltrion, and Pfizer launched biosimilars in 2019–2020, capturing significant market share.
2. How does biosimilar adoption impact pricing strategies?
Biosimilar entry drives downward pricing, pressuring brand manufacturers to negotiate discounts or develop next-generation therapies.
3. What is the outlook for Rituximab in autoimmune disorders?
Market expansion in autoimmune indications sustains demand, but biosimilar competition limits pricing growth.
4. Are there regulatory changes affecting Rituximab pricing?
Yes. In the U.S., CMS proposed policies to cap biosimilar prices and incentivize rebate strategies, potentially influencing net prices.
5. Will new therapies replace Rituximab?
Emerging biologics with different mechanisms, like obinutuzumab, could replace Rituximab in some indications, impacting overall market dynamics.
References
[1] IMS Health. (2022). Global Oncology Market Report.
[2] FDA. (2018). Patent and Exclusivity Data for Rituximab.
[3] IQVIA. (2022). Biosimilar Market Tracker.
[4] European Medicines Agency. (2023). Biosimilar Guidelines.
[5] Reuters. (2023). Biosimilar Pricing and Market Trends.
